Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Non Small Cell Lung Cancer NSCLC × tremelimumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 4 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Small Cell Lung Carcinoma 2 Liver Neoplasms 2 Urothelial Cancer 1 Recurrence 1 Non Small Cell Lung Cancer NSCLC 1 Non - Small Cell Lung Cancer NSCLC 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Renal Cell 1 Carcinoma 1

Interventions

tremelimumab 1 durvalumab 1 Pemetrexed 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03164616 2026-03-13

POSEIDON

AstraZeneca

Phase 3 Active not recruiting

1,186 enrolled 26 charts 1 FDA

Non Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡